Fig. 5: mOVA2 and mRIPO(H3.3) induced epitope-specific CD8 T cell responses in vivo. | Nature Communications

Fig. 5: mOVA2 and mRIPO(H3.3) induced epitope-specific CD8 T cell responses in vivo.

From: Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity

Fig. 5

a, b IFN-γ ELISPOT showing generation of SIINFEKL-specific CD8 T cells upon i.m. immunization of hCD155-tg mice with mOVA2. Cells were either left unstimulated or stimulated with peptide (SIINFEKL or MOG negative control); Concanavalin A stimulation (positive control) is shown in Supplementary Fig. 14. c, d H2Kb-SIINFEKL pentamer staining of peripheral blood, gated on CD11b−CD19− cells, showing % CD8 T cells that are SIINFEKL-specific. e, f HLA-A2-RMSAPSTGGV tetramer staining of peripheral blood, gated as in (c, d), showing % CD8 T cells that are RMSAPSTGGV-specific upon i.m. immunization of AAD_hCD155-tg mice with Complete Freund’s Adjuvant (CFA) and RMSAPSTGGV peptide emulsion, or with mRIPO(H3.3). c, f The gating strategy employed is shown in Supplementary Fig. 15. a, d, e Asterisks denote statistical significance between groups determined by RM-ANOVA protected Tukey’s- (a) or 1-way ANOVA protected Sidak’s post hoc test (d, e). All experiments were performed twice and representative results are shown. Error bars denote SEM. a mRIPOδ6 (n = 9), poly(I:C) (n = 3), poly(I:C) + SIINFEKL (n = 9), mRIPOδ6 + SIINFEKL (n = 9), mOVA2 (n = 10). d mRIPOδ6 (n = 9), poly(I:C) (n = 3), poly(I:C) + SIINFEKL (n = 10), mRIPOδ6 + SIINFEKL (n = 10), mOVA2 (n = 9). e mRIPOδ6 (n = 3), CFA + RMSAPSTGGV (n = 2), mRIPO(H3.3) (n = 3); n = number of mice. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Back to article page